Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Breast Cancer Clinical Trial

Official title:

A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04769050
• Other study ID #: DOLPHIN
• Status: Recruiting
• Start date: February 18, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: April 2022
• Source: Fudan University
• Contact: Xichun Hu, MD, PhD
• Phone: 64175590
• Email: huxicun[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment

Description:

Participants participated in the screening period visit, and received HER2-PET and 18 F-FDG PET/CT examinations before receiving tumor treatment, after receiving 2 cycles of chemotherapy, and after disease progression. Patients of first-line received docetaxel combined with trastuzumab±pertuzumab regimen, and patients of second-line received T-DM1 monotherapy or capecitabine combined with pyrrotinib regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects voluntarily joined the study, signed informed consent, and had good compliance.

2. Female patients aged over 18 years (including cutoff value).

3. an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

4. Patients with HER2 positive recurrent or metastatic breast cancer confirmed by histopathology.

5. At least one extracranial measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.

6. Previously received no more than 1 prior lines of systemic chemotherapy for metastatic breast cancer

7. Life expectancy = 12 weeks.

8. Adequate function of major organs meets the following requirements (no blood components and cell growth factors have been used within 14 days before randomization):

• Neutrophils = 1.5×10^9/L

• Platelets = 75×10^9/L

• Hemoglobin = 80g/L

• Total bilirubin= 1.5 × the upper limit of normal (ULN)

• ALT and AST = 3 × ULN

• BUN and Cr = 1.5 × ULN

• Left ventricular ejection fraction (LVEF) = 50%

• QTcF(Fridericia correction) = 470 ms

Exclusion Criteria:

1. The subject has untreated central nervous system (CNS) metastases.

2. Patients who have undergone systemic, radical brain or meningeal metastasis (radiotherapy or surgery), but have been confirmed to have been stable for at least 4 weeks, and who have stopped systemic hormonal therapy for more than 2 weeks without clinical symptoms can be included.

3. Received systemic therapy such as chemotherapy, molecular targeted therapyment;received endocrine therapy within 2 weeks before enrollment.

4. Patients with other malignant tumors within 3 years or at the sametime(except for cured skin basal cell carcinoma and cervical carcinomain situ).

5. Have undergone major surgical procedures or significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgery.

6. Pregnant women, lactating female, or women of childbearing age who are unwilling to take effective contraceptive measures.

7. Have a history of allergies to the drug components of this regimen.

8. Patients with active HBV and HCV infection; stable hepatitis B after drug treatment (HBV virus copy number is higher than the upper limit of reference value) and cured hepatitis C patients (HCV virus copy number exceeds the lower limit of detection method).

9. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, history of organ transplantation.

10. History of cardiac dysfunction, include(1)angina (2)clinical significant arrythmia or require drug intervention (3)myocardial infarction (4)heart failure (5) other cardiac dysfunction (judged by the physician); any cardiac or nephric abnormal = grade 2 found in screening.

11. Female patients who are pregnancy, lactation or women who are ofchildbearing potential tested positive in baseline pregnancy test.

12. Childbearing female who refuse to accept any contraception practice.

13. Determined by the physician, any serious coexisting disease might be harmful to the patient's safety or avoid the patients from accomplishing the treatment(e.g serious hypertension, diabetes, thyroid dysfunction,active infection etc.).

14. History of neurological or psychiatric disorders, including epilepsy or dementia.

15. Severe infections within 4 weeks prior to first dose (eg, intravenous infusion of antibiotics, antifungal or antiviral drugs according to clinical protocols), or unexplained fever (T > 38.3 °C ) during screening or prior to first administration

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Drug:
• Docetaxel combined with Trastuzumab±Pertuzumab
Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
• T-DM1 or Capecitabine combined with Pyrotinib regimen.
T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The correlation between the change of HER2-PET at baseline and after 2 courses of treatment and ORR.	The correlation between the percent change in standardized uptake value (SUV) on 68Ga-Affibody HER-2 Imaging PET at baseline and after 2 courses of treatment and objective response rate(ORR).	2 year
Secondary	The correlation between the change of HER2-PET at baseline and after 2 courses of treatment and PFS	The correlation between the percent change in SUV on 68Ga-Affibody HER-2 Imaging PET at baseline and after 2 courses of treatment and progression-free survival(PFS).	2 year
Secondary	The correlation between baseline HER2 expression and ORR, PFS	The correlation between the baseline SUVmax on 68Ga-Affibody HER-2 Imaging PET and ORR, PFS.	2 year
Secondary	The correlation between heterogeneity of baseline HER2 expression and ORR, PFS	The correlation between heterogeneity of the baseline SUVmax on 68Ga-Affibody HER-2 Imaging PET and ORR, PFS.	2 year
Secondary	To explore the condition of HER2-PET when PD.	To detection the change in SUVmax on 68Ga-Affibody HER-2 Imaging PET when progressive disease(PD).	2 year